Talon Private Wealth LLC Takes $616,000 Position in Abbott Laboratories $ABT

Talon Private Wealth LLC bought a new position in shares of Abbott Laboratories (NYSE:ABT) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,998 shares of the healthcare product maker’s stock, valued at approximately $616,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. State Street Corp raised its position in Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares in the last quarter. Capital International Investors lifted its holdings in Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares during the period. J. Stern & Co. LLP lifted its holdings in Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after acquiring an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors boosted its position in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after purchasing an additional 400,400 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.8%

Shares of ABT opened at $108.15 on Thursday. The stock has a 50 day moving average price of $92.72 and a 200 day moving average price of $100.73. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a market capitalization of $188.38 billion, a price-to-earnings ratio of 35.00, a PEG ratio of 2.08 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same quarter last year, the firm posted $1.26 EPS. The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be given a dividend of $0.63 per share. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS reaffirmed a Buy rating on Abbott, supporting the view that the recent pullback has created an attractive entry point. UBS Issues a Buy Rating on Abbott Laboratories
• Positive Sentiment: TD Cowen maintained its Buy rating and set a $115 price target, citing a strengthening nutrition franchise and 2026 growth opportunities. Abbott Laboratories Buy Rating Backed by Growth Drivers
• Positive Sentiment: Recent quarterly results exceeded expectations, with earnings and revenue above consensus and year-over-year revenue growth of 13%. Coverage also highlights record results and raised outlooks during the current earnings season. Companies Reported Record Results and Raised Guidance
• Positive Sentiment: Analysts continue to see long-term expansion in diabetes care, oncology diagnostics and heart-care devices, while Erste Group slightly raised its 2027 EPS forecast to $6.06 from $6.05. Abbott Growth Trends
• Neutral Sentiment: Abbott began a roughly 1,000-patient real-world study of its TriClip heart-valve repair system. The study could strengthen adoption, but it also underscores rising competition from Edwards Lifesciences. Abbott Starts TriClip Study
• Neutral Sentiment: A personal-finance article included Abbott among dividend stocks suitable for long-term passive income, but it offered limited new company-specific information. Dividend Stocks for Passive Income
• Negative Sentiment: UBS lowered its price target from $135 to $125 while retaining a Buy rating, signaling somewhat less near-term upside despite continued confidence in Abbott’s fundamentals.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ABT shares. JPMorgan Chase & Co. lifted their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Mizuho decreased their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Finally, Citigroup raised their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.17.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.